4DMedical And 2 Other Australian Growth Stocks To Watch

With US 10 year Treasury yields above 5% for the first time in almost two decades, growth stories are suddenly being judged against much higher hurdle rates. That puts a premium on Australian companies that not only have solid balance sheets but are also expected to lift earnings meaningfully over the next few years. This article highlights three options from a high growth shortlist that fit that brief.

The three stocks below are only a small sample from this high growth shortlist. The full screen surfaced 92 more companies with equally compelling stories that are not covered here. To identify, compare, and analyze those opportunities with the same filters used for this article, head straight to the Healthy high growth potential screener.

4DMedical (ASX:4DX)

Overview: 4DMedical develops non invasive respiratory imaging hardware and software that measure lung function and disease progression for clinicians and drug developers.

Operations: 4DMedical generates about A$7.1 million from lung function analysis technology, with roughly A$6.9 million from the United States and A$0.2 million from Australia.

Market Cap: A$2.4 billion

4DMedical taps directly into the screener’s healthy high growth potential theme by pairing lung imaging tools with real world commercial channels through large partners.

"Partnership with Philips promised a $10Million USD minimum order commitment contract over the next 2 years starting December 2025 (over 2026 and 2027). Philips has added 4DMedicals CT:VQ technology as an official product on their catalog in North America."

What happens if the early hospital rollouts turn into routine usage will likely matter more for 4DMedical’s future margins than any model today assumes.

If that adoption curve really starts to accelerate, read the full narrative for 4DMedical to see how that scenario, funding needs and execution risk all tie together.

Neuren Pharmaceuticals (ASX:NEU)

Overview: Neuren Pharmaceuticals develops therapies for rare neurological conditions, with DAYBUE for Rett syndrome anchoring its role in the Healthy high growth potential theme.

Operations: Neuren generates about A$69.5 million from commercial products, almost entirely sourced from customers in the United States.

Market Cap: A$2.6 billion

Neuren Pharmaceuticals matters for this screener because DAYBUE is already on the market, tying current sales to potential multi year earnings expansion if further indications are approved.

"Planned expansion into international markets, such as Canada, Europe, and Japan, offers significant long-term growth prospects and additional revenue streams due to higher royalty rates outside the U.S."

A shift in a key partner’s execution or pricing power could materially affect how any future growth flows through to margins.

That margin risk is only half the story, and the full narrative for Neuren Pharmaceuticals maps how Neuren Pharmaceuticals could see royalties, indications and sentiment accelerate together.

Megaport (ASX:MP1)

Overview: Megaport runs a software defined network that lets enterprises buy on demand data center and multi cloud connectivity across regions.

Operations: Megaport generates about A$312 million in revenue, with roughly A$198 million from the Americas, A$70 million from Asia Pacific, and A$44 million from Europe.

Market Cap: A$4.6 billion

Megaport matters for the Healthy high growth potential screener because its SDN driven interconnection platform directly links rising cloud usage to scalable earnings power.

"Skyrocketing enterprise bandwidth, surging AI/cloud adoption, and the rapid proliferation of data centers are combining to create secular tailwinds. Megaport's automation, global reach, and software-defined architecture give it strong potential to be a core connectivity backbone for AI factories, data-native SaaS, and hybrid enterprise networks."

What happens if one key funding and profitability assumption shifts will likely shape how much of that top line potential reaches long term margins.

If that margin mix is what you care about, read the full narrative for Megaport to see how Megaport’s model could scale, stall or radically decouple profitability from volume growth.

Seeking Fresh Alternatives Before They Fly

Fresh ideas do not stay quiet for long. Once momentum hits, entry windows narrow fast and pricing power shifts to the crowd. Scan these curated lists before they are fully caught, and get in early.

• Spot resilient income anchors while they are still under the radar by scanning the 3 dividend fortresses that screens for yield strength and balance sheet support.
• Hunt for early leaders in automation by checking the curated 92 robotics and automation stocks filtering businesses tied to real world robotics and productivity demand.
• Explore AI infrastructure demand at the picks and shovels level by running the focused 85 AI infrastructure stocks to surface enablers of data center and compute expansion.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com